Know Cancer

or
forgot password


Phase 2
18 Years
N/A
Not Enrolling
Both
Carcinoma, Non-Small-Cell Lung

Thank you

Trial Information

Inclusion Criteria


Inclusion:

- Histological or cytological confirmed Stage IIIB NSCLC with malignant pleural
effusions, or Stage IV NSCLC or recurrent NSCLC

- No previous chemotherapy for NSCLC

- Have one lesion that is bidimensionally measurable by physical exam, MRI, or CT
greater than 1 cm in diameter

- Specified lab parameters

- Life expectancy of at least 12 weeks

- ECOG performance status of 0 or 1

- Understand requirements of study

- Agree to use effective contraceptive methods

Exclusion:

- Have CNS metastases

- Have any active cancer in addition ot NSCLC

- Participated in clinical trial involving conventional or investigational drugs within
previous 4 weeks

- Have any contraindication to paclitaxel or carboplatin

- Have had Grade 3 or greater peripheral neuropathies

- Be pregnant or lactating

- Have a history of myocardial infarction or angina pectoris/angina in the last 6
months

- Have had significant (30 mL or more) hemoptysis with the past 3 months

- Have an active infection

- Have a history of bleeding diathesis, hypercoagulable condition, or an active
bleeding disorder

- Be receiving concurrent treatment with therapeutic doses of heparin or coumadin

- Have had major surgery within 4 weeks of stating therapy

- Have additional uncontrolled serious medical conditions or psychiatric illness

- Received rhAngiostatin in other clinical protocols

Type of Study:

Interventional

Study Design:

Primary Purpose: Treatment

Authority:

United States: Food and Drug Administration

Study ID:

ANG-CL-004

NCT ID:

NCT00049790

Start Date:

Completion Date:

December 2004

Related Keywords:

  • Carcinoma, Non-Small-Cell Lung
  • Advanced non-small cell lung cancer
  • Carcinoma
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location

Indiana Cancer Pavilion, Indiana UniversityIndianapolis, Indiana  46202